Candel Therapeutics, Inc. (CADL)
Candel Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Needham, MA, US. The stock last traded at $13.60, up 5.72% on the session, giving a market capitalisation of $996.1M. On trailing twelve-month figures it carries a trailing P/E of -9.64, a net margin of 0.0%. Its beta of -0.50 implies it has historically moved less than the broad market.
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.
Candel Therapeutics, Inc. is most often compared with the following Healthcare names: